Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Authors
Spanjaart, A. M.Ljungman, P.
de La Camara, R.
Tridello, G.
Ortiz-Maldonado, V.
Urbano-Ispizua, A.
Barba, P.
Kwon, M.
Caballero, D.
Sesques, P.
Bachy, E.
Di Blasi, R.
Thieblemont, C.
Calkoen, F.
Mutsaers, P.
Maertens, J.
Giannoni, L.
Nicholson, E.
Collin, M.
Vaz, C. P.
Metafuni, E.
Martinez-Lopez, J.
Dignan, F. L.
Ribera, J. M.
Nagler, A.
Folber, F.
Sanderson, R.
Bloor, Adrian
Ciceri, F.
Knelange, N.
Ayuk, F.
Kroger, N.
Kersten, M. J.
Mielke, S.
Affiliation
Adult Leukaemia and Bone Marrow Transplant Unit, Christie NHS Trust Hospital, University of Manchester, Manchester, UK.Issue Date
2021
Metadata
Show full item recordCitation
Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group [Internet]. Leukemia. Springer Science and Business Media LLC; 2021.Journal
LeukemiaDOI
10.1038/s41375-021-01466-0PubMed ID
34750508Additional Links
https://dx.doi.org/10.1038/s41375-021-01466-0Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41375-021-01466-0
Scopus Count
Collections
Related articles
- Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.
- Authors: Spanjaart AM, Ljungman P, Tridello G, Schwartz J, Martinez-Cibrián N, Barba P, Kwon M, Lopez-Corral L, Martinez-Lopez J, Ferra C, Di Blasi R, Ghesquieres H, Mutsaers P, Calkoen F, Jak M, van Doesum J, Vermaat JSP, van der Poel M, Maertens J, Gambella M, Metafuni E, Ciceri F, Saccardi R, Nicholson E, Tholouli E, Matthew C, Potter V, Bloor A, Besley C, Roddie C, Wilson K, Nagler A, Campos A, Petersen SL, Folber F, Bader P, Finke J, Kroger N, Knelange N, de La Camara R, Kersten MJ, Mielke S
- Issue date: 2024 Sep
- Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy.
- Authors: Dong R, Jiang S, Chen Y, Ma Y, Sun L, Xing C, Zhang S, Yu K
- Issue date: 2021 Dec
- Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials.
- Authors: Xu XJ, Zhao HZ, Tang YM
- Issue date: 2013 Feb
- Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight.
- Authors: Jamani K, Duggan P, Neri P, Bahlis N, Jimenez-Zepeda VH
- Issue date: 2016
- Updates on CAR T-cell therapy in B-cell malignancies.
- Authors: Jacoby E, Shahani SA, Shah NN
- Issue date: 2019 Jul